Active substance
Results for the substance dacomitinib
3 results
About this active substance
Dacomitinib is a medication used for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. It works by irreversibly inhibiting the EGFR receptor, blocking signals that promote cancer cell growth.
The medication is taken orally, in tablet form, and is specifically indicated for patients with specific EGFR mutations. It is used as a first-line therapy to slow disease progression.
Common side effects include diarrhea, skin rash, dry skin, and stomatitis. In rare cases, severe reactions such as interstitial pneumonitis may occur. It is important to inform your doctor about any side effects.
Consult your doctor to discuss the benefits and risks of treatment with Dacomitinib. Regular monitoring is essential to assess treatment response and manage potential complications.
The medication is taken orally, in tablet form, and is specifically indicated for patients with specific EGFR mutations. It is used as a first-line therapy to slow disease progression.
Common side effects include diarrhea, skin rash, dry skin, and stomatitis. In rare cases, severe reactions such as interstitial pneumonitis may occur. It is important to inform your doctor about any side effects.
Consult your doctor to discuss the benefits and risks of treatment with Dacomitinib. Regular monitoring is essential to assess treatment response and manage potential complications.
-
-
VIZIMPRO 45mg film-coated tablets PFIZER ORIGINAL MEDICINE
-
VIZIMPRO 15mg film-coated tablets PFIZER ORIGINAL MEDICINE